Dr. Mumper received a B.A. in Chemistry and Ph.D. in Pharmaceutics/Drug Delivery from the
University of Kentucky in 1988 and 1991, respectively.  

Dr. Mumper’s research program is focused primarily in five areas:

1)  nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles
     for tumor and dendritic cell targeting and vaccines

2)  biocompatibility, hemocompatibility, and toxicology of nanoparticles and nanomaterials

3)  drug-polymer conjugates

4)  mucoadhesive gels and thin-films for (trans)mucosal delivery of drugs, vaccines, and microbicides

5)  anticancer and anti-inflammatory properties of berries and berry extracts

Recent publications on PubMed

Dr. Mumper is the John A. McNeill Distinguished Professor in the Molecular Pharmaceutics Division in the School of Pharmacy, and the first Director of the Center for Nanotechnology in Drug Delivery at The University of North Carolina at Chapel Hill. 

From 1999-2007, Dr. Mumper was a faculty member in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Kentucky.  He served as Vice Chair of the Department from 1994 to 1997. Also, from 1999-2006, Dr. Mumper was the Associate Director of the Center for Pharmaceutical Science & Technology (CPST).  Prior to becoming a for-profit company in 2007, the CPST was a unique university-based fully-integrated FDA-registered GMP pharmaceutical manufacturing facility.  Dr. Mumper led the CPST’s efforts to complete full product development resulting in the successful submission of seven different INDs and commencement of human clinical trials with both industrial and university partners. 

After completing a post-doctoral fellowship in the Center for Bioengineering at the University of Washington in 1992, Dr. Mumper held various product development positions in the pharmaceutical/biotech industry working for Burroughs-Wellcome Co. in North Carolina and GeneMedicine, Inc. and Virotex Corporation, both in The Woodlands, Texas.  Since returning to academia in 1999, Dr. Mumper has received over $6.3 million in research grants/contracts as Principal Investigator (and over $8.3 million total). Dr. Mumper has more than 190 scientific publications/abstracts and 35 patents or patents pending. Dr. Mumper serves on the Editorial Board of three pharmaceutical journals and is an ad-hoc member of several different scientific review panels for the National Institutes of Health.

In 2006, he received the AAPS Lipid-based Drug Delivery Award sponsored by Gattefossé Corporation and the American Association of Pharmaceutical Scientists (AAPS).

In 2007, Dr. Mumper was recognized by the University of Kentucky (UK) Alumni Association as one of six “Great Teachers” at UK.  This award is the oldest, continuously given award for teaching on UK’s campus.              

Dr. Mumper has co-founded three companies; NanoMed Pharmaceuticals Inc. based in Kalamazoo, Michigan, and Four Tigers LLC and Berryceuticals LLC both based in Paris and Lexington, Kentukcy.  These companies were founded on technology developed in his laboratories.